Adjuvanted HLA-supertype restricted subdominant peptides induce new T-cell immunity during untreated HIV-1-infection

Clinical Immunology

Volumn 146, Issue 2, 2013, Pages 120-130

  Karlsson, Ingrid ^a   Brandt, Lea ^a   Vinner, Lasse ^a,d   Kromann, Ingrid ^a   Andreasen, Lars Vibe ^a   Andersen, Peter ^a   Gerstoft, Jan ^b   Kronborg, Gitte ^c   Fomsgaard, Anders ^a  

^a STATENS SERUM INSTITUT   (Denmark)

^b Mental Health Services CPH   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

CAF01 adjuvant; ; HIV 1; ; HLA supertypes; ; Subdominant epitopes; ; Therapeutic vaccine

Indexed keywords

ADJUVANT; CAF 01; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MACROPHAGE INFLAMMATORY PROTEIN 1BETA; PLACEBO; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG SAFETY; ENZYME LINKED IMMUNOSPOT ASSAY; FLOW CYTOMETRY; FOLLOW UP; GENOTYPE; HEMATOLOGY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNIZATION; IMMUNOGENICITY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; SINGLE BLIND PROCEDURE; VIRUS LOAD;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HIV INFECTIONS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; IMMUNODOMINANT EPITOPES; MALE; MIDDLE AGED; PEPTIDES; SINGLE-BLIND METHOD; YOUNG ADULT;

EID: 84872351363     PISSN: 15216616     EISSN: 15217035     Source Type: Journal    
DOI: 10.1016/j.clim.2012.12.005     Document Type: Article

References (47)

1. Autran B., Carcelain G., Combadiere B., Debre P. Therapeutic vaccines for chronic infections. Science 2004, 305:205-208.
2. Sette A., Sidney J. Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism. Immunogenetics 1999, 50:201-212.
3. Sidney J., Peters B., Frahm N., Brander C., Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008, 9:1.
4. Frahm N., Kiepiela P., Adams S., Linde C.H., Hewitt H.S., Sango K., Feeney M.E., Addo M.M., Lichterfeld M., Lahaie M.P., Pae E., Wurcel A.G., Roach T., St John M.A., Altfeld M., Marincola F.M., Moore C., Mallal S., Carrington M., Heckerman D., Allen T.M., Mullins J.I., Korber B.T., Goulder P.J., Walker B.D., Brander C. Control of human immunodeficiency virus replication by cytotoxic T lymphocytes targeting subdominant epitopes. Nat. Immunol. 2006, 7:173-178.
5. Gallimore A., Dumrese T., Hengartner H., Zinkernagel R.M., Rammensee H.G. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T cell responses to naturally processed peptides. J. Exp. Med. 1998, 187:1647-1657.
6. Holtappels R., Simon C.O., Munks M.W., Thomas D., Deegen P., Kuhnapfel B., Daubner T., Emde S.F., Podlech J., Grzimek N.K., Oehrlein-Karpi S.A., Hill A.B., Reddehase M.J. Subdominant CD8 T-cell epitopes account for protection against cytomegalovirus independent of immunodomination. J. Virol. 2008, 82:5781-5796.
7. + T-cell responses are involved in durable control of AIDS virus replication. J. Virol. 2007, 81:3465-3476.
8. Andresen B.S., Vinner L., Tang S., Bragstad K., Kronborg G., Gerstoft J., Corbet S., Fomsgaard A. Characterization of near full-length genomes of HIV type 1 strains in Denmark: basis for a universal therapeutic vaccine. AIDS Res. Hum. Retroviruses 2007, 23:1442-1448.
9. + T-lymphocyte cross-recognition may explain the immune reaction in infected individuals. APMIS 2007, 115:757-768.
10. Vinner L., Holmgren B., Jensen K.J., Esbjornsson J., Borggren M., Hentze J.L., Karlsson I., Andresen B.S., Gram G.J., Kloverpris H., Aaby P., Da Silva Z.J., Fenyo E.M., Fomsgaard A. Sequence analysis of HIV-1 isolates from Guinea-Bissau: selection of vaccine epitopes relevant in both West African and European countries. APMIS 2011, 119:487-497.
11. Karlsson I., Kloverpris H., Jensen K.J., Stryhn A., Buus S., Karlsson A.C., Vinner L., Goulder P., Fomsgaard A. Identification of conserved subdominant HIV type 1 CD8 T cell epitopes restricted within common HLA supertypes for therapeutic HIV type 1 vaccines. AIDS Res. Hum. Retroviruses 2012, 23:1434-1443.
12. Altfeld M., Rosenberg E.S. The role of CD4(+) T helper cells in the cytotoxic T lymphocyte response to HIV-1. Curr. Opin. Immunol. 2000, 12:375-380.
13. Agger E.M., Rosenkrands I., Hansen J., Brahimi K., Vandahl B.S., Aagaard C., Werninghaus K., Kirschning C., Lang R., Christensen D., Theisen M., Follmann F., Andersen P. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PLoS One 2008, 3:e3116.
14. Davidsen J., Rosenkrands I., Christensen D., Vangala A., Kirby D., Perrie Y., Agger E.M., Andersen P. Characterization of cationic liposomes based on dimethyldioctadecylammonium and synthetic cord factor from M. tuberculosis (trehalose 6,6'-dibehenate)-a novel adjuvant inducing both strong CMI and antibody responses. Biochim. Biophys. Acta 2005, 1718:22-31.
15. Schoenen H., Bodendorfer B., Hitchens K., Manzanero S., Werninghaus K., Nimmerjahn F., Agger E.M., Stenger S., Andersen P., Ruland J., Brown G.D., Wells C., Lang R. Cutting edge: Mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 2010, 184:2756-2760.
16. Lindenstrom T., Agger E.M., Korsholm K.S., Darrah P.A., Aagaard C., Seder R.A., Rosenkrands I., Andersen P. Tuberculosis subunit vaccination provides long-term protective immunity characterized by multifunctional CD4 memory T cells. J. Immunol. 2009, 182:8047-8055.
17. Gram G.J., Karlsson I., Agger E.M., Andersen P., Fomsgaard A. A novel liposome-based adjuvant CAF01 for induction of CD8(+) cytotoxic T-lymphocytes (CTL) to HIV-1 minimal CTL peptides in HLA-A*0201 transgenic mice. PLoS One 2009, 4:e6950.
18. Fomsgaard A., Karlsson I., Gram G., Schou C., Tang S., Bang P., Kromann I., Andersen P., Andreasen L.V. Development and preclinical safety evaluation of a new therapeutic HIV-1 vaccine based on 18 T-cell minimal epitope peptides applying a novel cationic adjuvant CAF01. Vaccine 2011, 29:7067-7074.
19. Christensen D., Agger E.M., Andreasen L.V., Kirby D., Andersen P., Perrie Y. Liposome-based cationic adjuvant formulations (CAF): past, present, and future. J. Liposome Res. 2009, 19:2-11.
20. Corbet S., Nielsen H.V., Vinner L., Lauemoller S., Therrien D., Tang S., Kronborg G., Mathiesen L., Chaplin P., Brunak S., Buus S., Fomsgaard A. Optimization and immune recognition of multiple novel conserved HLA-A2, human immunodeficiency virus type 1-specific CTL epitopes. J. Gen. Virol. 2003, 84:2409-2421.
21. + T-cell responses during chronic untreated HIV-1 infection by immunization with subdominant cytotoxic T-lymphocyte epitopes. AIDS 2009, 23:1329-1340.
22. Moodie Z., Price L., Gouttefangeas C., Mander A., Janetzki S., Lower M., Welters M.J., Ottensmeier C., van der Burg S.H., Britten C.M. Response definition criteria for ELISPOT assays revisited. Cancer Immunol. Immunother. 2010, 59:1489-1501.
23. Precopio M.L., Betts M.R., Parrino J., Price D.A., Gostick E., Ambrozak D.R., Asher T.E., Douek D.C., Harari A., Pantaleo G., Bailer R., Graham B.S., Roederer M., Koup R.A. Immunization with vaccinia virus induces polyfunctional and phenotypically distinctive CD8(+) T cell responses. J. Exp. Med. 2007, 204:1405-1416.
24. Roederer M., Nozzi J.L., Nason M.C. SPICE: exploration and analysis of post-cytometric complex multivariate datasets. Cytometry A 2011, 79:167-174.
25. + T cells. Blood 2006, 107:4781-4789.
26. Karlsson A.C., Martin J.N., Younger S.R., Bredt B.M., Epling L., Ronquillo R., Varma A., Deeks S.G., McCune J.M., Nixon D.F., Sinclair E. Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells. J. Immunol. Methods 2003, 283:141-153.
27. Seder R.A., Darrah P.A., Roederer M. T-cell quality in memory and protection: implications for vaccine design. Nat. Rev. Immunol. 2008, 8:247-258.
28. Kloverpris H.N., Karlsson I., Thorn M., Buus S., Fomsgaard A. Immune hierarchy among HIV-1 CD8+ T cell epitopes delivered by dendritic cells depends on MHC-I binding irrespective of mode of loading and immunization in HLA-A*0201 mice. APMIS 2009, 117:849-855.
29. Yewdell J.W., Bennink J.R. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999, 17:51-88.
30. Rao X., Hoof I., Costa A.I., van Baarle D., Kesmir C. HLA class I allele promiscuity revisited. Immunogenetics 2011, 63:691-701.
31. Erup Larsen M., Kloverpris H., Stryhn A., Koofhethile C.K., Sims S., Ndung'u T., Goulder P., Buus S., Nielsen M. HLArestrictor-a tool for patient-specific predictions of HLA restriction elements and optimal epitopes within peptides. Immunogenetics 2011, 63:43-55.
32. Esbjornsson J., Mild M., Mansson F., Norrgren H., Medstrand P. HIV-1 molecular epidemiology in Guinea-Bissau, West Africa: origin, demography and migrations. PLoS One 2011, 6:e17025.
33. Fischer W., Perkins S., Theiler J., Bhattacharya T., Yusim K., Funkhouser R., Kuiken C., Haynes B., Letvin N.L., Walker B.D., Hahn B.H., Korber B.T. Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants. Nat. Med. 2007, 13:100-106.
34. Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., Dorrell L., Dong T., Korber B., McMichael A.J., Hanke T. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One 2007, 2:e984.
35. Anderson D.E., Malley A., Benjamini E., Gardner M.B., Torres J.V. Hypervariable epitope constructs as a means of accounting for epitope variability. Vaccine 1994, 12:736-740.
36. Oliveira E., Jimenez-Clavero M.A., Nunez J.I., Sobrino F., Andreu D. Analysis of the immune response against mixotope peptide libraries from a main antigenic site of foot-and-mouth disease virus. Vaccine 2005, 23:2647-2657.
37. Hewer R., Meyer D. Peptide immunogens based on the envelope region of HIV-1 are recognized by HIV/AIDS patient polyclonal antibodies and induce strong humoral immune responses in mice and rabbits. Mol. Immunol. 2003, 40:327-335.
38. Pedroza-Roldan C., Charles-Nino C., Saavedra R., Govezensky T., Vaca L., Avaniss-Aghajani E., Gevorkian G., Manoutcharian K. Variable epitope library-based vaccines: shooting moving targets. Mol. Immunol. 2009, 47:270-282.
39. Addo M.M., Yu X.G., Rathod A., Cohen D., Eldridge R.L., Strick D., Johnston M.N., Corcoran C., Wurcel A.G., Fitzpatrick C.A., Feeney M.E., Rodriguez W.R., Basgoz N., Draenert R., Stone D.R., Brander C., Goulder P.J., Rosenberg E.S., Altfeld M., Walker B.D. Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. J. Virol. 2003, 77:2081-2092.
40. Betts M.R., Ambrozak D.R., Douek D.C., Bonhoeffer S., Brenchley J.M., Casazza J.P., Koup R.A., Picker L.J. Analysis of total human immunodeficiency virus (HIV)-specific CD4(+) and CD8(+) T-cell responses: relationship to viral load in untreated HIV infection. J. Virol. 2001, 75:11983-11991.
41. Grossman Z., Meier-Schellersheim M., Paul W.E., Picker L.J. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat. Med. 2006, 12:289-295.
42. van Grevenynghe J., Cubas R.A., Noto A., DaFonseca S., He Z., Peretz Y., Filali-Mouhim A., Dupuy F.P., Procopio F.A., Chomont N., Balderas R.S., Said E.A., Boulassel M.R., Tremblay C.L., Routy J.P., Sekaly R.P., Haddad E.K. Loss of memory B cells during chronic HIV infection is driven by Foxo3a- and TRAIL-mediated apoptosis. J. Clin. Invest. 2011, 121:3877-3888.
43. + T cells. J. Exp. Med. 2004, 200:701-712.
44. Harari A., Petitpierre S., Vallelian F., Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004, 103:966-972.
45. Saez-Cirion A., Lacabaratz C., Lambotte O., Versmisse P., Urrutia A., Boufassa F., Barre-Sinoussi F., Delfraissy J.F., Sinet M., Pancino G., Venet A., E.P.H.I.V.C.S.G. Agence Nationale de Recherches sur le Sida HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:6776-6781.
46. Yamamoto T., Price D.A., Casazza J.P., Ferrari G., Nason M., Chattopadhyay P.K., Roederer M., Gostick E., Katsikis P.D., Douek D.C., Haubrich R., Petrovas C., Koup R.A. Surface expression patterns of negative regulatory molecules identify determinants of virus-specific CD8+ T-cell exhaustion in HIV infection. Blood 2011, 117:4805-4815.
47. + T cell responses by multiple immunological readouts reveals distinct specificities defined by function. J. Virol. 2011, 85:1275-1286.